Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Chia-Ling Wu

2PUBLICATIONS

6CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Jul 07, 2026

Oncogenic <i>PIK3CA</i> mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

|Jul 13, 2024

<i>TNFSF9</i> Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab.

Bunpei Isoda, Shuya Kandori, Tomokazu Sazuka

Pageof 1

Frequent Collaborators

1 joint publications

Bunpei Isoda

1 joint publications

Shuya Kandori

1 joint publications

Hiroaki Sato

1 joint publications

Bryan J Mathis

1 joint publications

Tomohiko Ichikawa

1 joint publications

Yu-Li Su

Frequent Collaborators

1 joint publications

Bunpei Isoda

1 joint publications

Shuya Kandori

1 joint publications

Hiroaki Sato

1 joint publications

Bryan J Mathis